Meribank Biotech Co., Ltd (TPEX:4724)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
9.06
-0.13 (-1.41%)
Aug 4, 2026, 1:51 PM CST

Meribank Biotech Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-81.47-94.71-125.35-102.13-99.19
Depreciation & Amortization
154.9583.2234.2832.1629.47
Other Amortization
0.460.812.25--
Loss (Gain) From Sale of Assets
--0.01-0.07--
Asset Writedown & Restructuring Costs
2.1-5.67--
Loss (Gain) From Sale of Investments
14.54-2.72--5.79-0.18
Loss (Gain) on Equity Investments
3.6311.935.415.424.51
Stock-Based Compensation
7.892.511.170.020.34
Provision & Write-off of Bad Debts
5.461.233.84-0.595.28
Other Operating Activities
-8.01-7.28-4.14-1.45-0.37
Change in Accounts Receivable
-33.03-29.9917.6-6.25-14.2
Change in Inventory
4.82-4.341.54-4.84-0.67
Change in Accounts Payable
-6.161.853.292.3-0.24
Change in Unearned Revenue
9.5922.8312.2210.5233.6
Change in Other Net Operating Assets
14.67-23.4212.5829.3118.66
Operating Cash Flow
89.45-38.09-29.7-41.33-23
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-3.84-248.61-5.8-4.15-7.21
Sale of Property, Plant & Equipment
-0.01---
Cash Acquisitions
-15.44-4.42-1.27-
Sale (Purchase) of Intangibles
-1.05-95.58-0.88-0.09-0.31
Sale (Purchase) of Real Estate
-11----
Investment in Securities
-131.9-14.4983.62-23.03-75.83
Other Investing Activities
-22.3-19.23-24.37-16.46-34.72
Investing Cash Flow
-170.08-362.4648.15-45.01-118.07

Financing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-175---
Long-Term Debt Repaid
-77.95-38.76-22.78-20.34-17.98
Net Debt Issued (Repaid)
-77.95136.24-22.78-20.34-17.98
Issuance of Common Stock
120-311.6-300
Other Financing Activities
-28.3429.947.03-0.32-0.2
Financing Cash Flow
13.71166.17295.85-20.66281.82

Net Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-0.73----
Net Cash Flow
-67.65-234.37314.3-106.99140.76

Free Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
85.62-286.7-35.5-45.48-30.2
Free Cash Flow Growth
-----
Free Cash Flow Margin
18.15%-78.24%-15.15%-25.25%-18.52%
Free Cash Flow Per Share
0.94-3.60-0.56-0.72-0.50
Levered Free Cash Flow
57.12-330.4-11.46-43.73-55.04
Unlevered Free Cash Flow
71.57-323.71-10.93-43.12-54.33

Additional Metrics

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
23.1110.70.850.991.13
Cash Income Tax Paid
0.070.03---
Change in Working Capital
-10.1-33.0647.2331.0437.15